N. Bergemann

3.0k total citations
23 papers, 329 citations indexed

About

N. Bergemann is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health. According to data from OpenAlex, N. Bergemann has authored 23 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Psychiatry and Mental health, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in N. Bergemann's work include Schizophrenia research and treatment (7 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Maternal Mental Health During Pregnancy and Postpartum (4 papers). N. Bergemann is often cited by papers focused on Schizophrenia research and treatment (7 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Maternal Mental Health During Pregnancy and Postpartum (4 papers). N. Bergemann collaborates with scholars based in Germany, United States and Sweden. N. Bergemann's co-authors include Peter Parzer, Jürgen Kopitz, C. Mundt, Ch. Mündt, B. Runnebaum, Franz Resch, Wolfgang Paulus, K. Sartor, Daniela Roesch-Ely and H. Baas and has published in prestigious journals such as Psychological Medicine, Schizophrenia Bulletin and Psychoneuroendocrinology.

In The Last Decade

N. Bergemann

22 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Bergemann Germany 9 150 47 44 40 38 23 329
Nicolás David Ramírez Spain 11 206 1.4× 86 1.8× 29 0.7× 44 1.1× 28 0.7× 27 481
Gerald Oppenheim Israel 12 127 0.8× 81 1.7× 52 1.2× 13 0.3× 62 1.6× 18 353
Ivo Caers Belgium 8 153 1.0× 57 1.2× 40 0.9× 7 0.2× 46 1.2× 10 327
Abdulla A.-B. Badawy United Kingdom 8 86 0.6× 26 0.6× 16 0.4× 43 1.1× 12 0.3× 24 468
Cheng‐Cheng Hsiao Taiwan 12 162 1.1× 86 1.8× 82 1.9× 19 0.5× 7 0.2× 20 412
Vicki L. Ellingrod United States 11 158 1.1× 168 3.6× 54 1.2× 76 1.9× 28 0.7× 15 487
Cherry W. Jackson United States 10 137 0.9× 24 0.5× 32 0.7× 33 0.8× 5 0.1× 21 347
Carla Conroy United States 14 404 2.7× 62 1.3× 111 2.5× 36 0.9× 16 0.4× 30 624
Xiaoyun Wang China 13 49 0.3× 67 1.4× 65 1.5× 13 0.3× 18 0.5× 26 418
Jacoline Neuteboom Netherlands 6 41 0.3× 31 0.7× 20 0.5× 25 0.6× 32 0.8× 7 415

Countries citing papers authored by N. Bergemann

Since Specialization
Citations

This map shows the geographic impact of N. Bergemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Bergemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Bergemann more than expected).

Fields of papers citing papers by N. Bergemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Bergemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Bergemann. The network helps show where N. Bergemann may publish in the future.

Co-authorship network of co-authors of N. Bergemann

This figure shows the co-authorship network connecting the top 25 collaborators of N. Bergemann. A scholar is included among the top collaborators of N. Bergemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Bergemann. N. Bergemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergemann, N., Berglind Jónsdóttir, Anna-Lena Nilsson, Mikael Lantz, & A. R. Lind. (2023). Prevalence of Thyroid Peroxidase and Thyroglobulin Autoantibodies in the Swedish Population. Experimental and Clinical Endocrinology & Diabetes. 131(9). 456–462. 2 indexed citations
2.
Hiemke, Christoph, N. Bergemann, M. Gerlach, et al.. (2022). The therapeutic reference range for olanzapine revised – how to combine old and new findings. Pharmacopsychiatry. 55(3). 172–173. 1 indexed citations
3.
4.
Franz, M., et al.. (2017). QLiS-SF: Development of a short form of the quality of life in schizophrenia questionnaire. BMC Psychiatry. 17(1). 149–149. 3 indexed citations
5.
Bergemann, N. & Wolfgang Paulus. (2016). Affektive Störungen in der Schwangerschaft: Therapie mit Antidepressiva und Mood Stabilizern. Der Nervenarzt. 87(9). 955–966. 2 indexed citations
6.
Bergemann, N. & Wolfgang Paulus. (2016). Affektive Störungen in der Schwangerschaft. Der Nervenarzt. 87(9). 955–966. 3 indexed citations
7.
Bergemann, N. & Wolfgang Paulus. (2016). Psychopharmakotherapie in der Schwangerschaft. Der Nervenarzt. 87(9). 943–954. 4 indexed citations
8.
Deuschle, Michael, Friedemann Paul, M. Brosz, et al.. (2013). Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study. Social Psychiatry and Psychiatric Epidemiology. 48(8). 1283–1288. 11 indexed citations
9.
Bergemann, N., et al.. (2009). Therapeutisches Drug-Monitoring von Psychopharmaka in der Schwangerschaft. Journal für Kardiologie (Krause & Pachernegg GmbH). 10(1). 38–40. 3 indexed citations
10.
Bergemann, N., et al.. (2008). High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychological Medicine. 38(8). 1195–1201. 28 indexed citations
11.
Strowitzki, T., et al.. (2007). Exazerbation einer schizoaffektiven Psychose nach In-vitro-Fertilisation mit Leuprorelinacetat. Der Nervenarzt. 78(6). 691–695. 3 indexed citations
12.
Bergemann, N., et al.. (2007). Estrogen and Comprehension of Metaphoric Speech in Women Suffering From Schizophrenia: Results of a Double-Blind, Placebo-Controlled Trial. Schizophrenia Bulletin. 34(6). 1172–1181. 38 indexed citations
13.
Bergemann, N., et al.. (2005). Valproate Lowers Plasma Concentrations of Olanzapine. Pharmacopsychiatry. 38(1). 1 indexed citations
14.
Bergemann, N., et al.. (2004). Olanzapine Plasma Concentration, Average Daily Dose, and Interaction with Co-Medication in Schizophrenic Patients. Pharmacopsychiatry. 37(2). 63–68. 69 indexed citations
15.
Roesch-Ely, Daniela, et al.. (2002). H2-Histamine Antagonist (Famotidine) Induced Adverse CNS Reactions with Long-Standing Secondary Mania and Epileptic Seizures. Pharmacopsychiatry. 35(4). 152–154. 21 indexed citations
16.
Bergemann, N., et al.. (2002). Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Archives of Women s Mental Health. 5(3). 119–126. 43 indexed citations
17.
Bergemann, N., et al.. (1999). Asymptomatic Pancreatitis Associated with Clozapine. Pharmacopsychiatry. 32(2). 78–80. 23 indexed citations
18.
Bergemann, N., et al.. (1996). On the hypoestrogen hypothesis in female schizophrenia: Preliminary results. Schizophrenia Research. 18(2-3). 158–158. 2 indexed citations
19.
Bergemann, N., H. Baas, & P.-A. Fischer. (1994). [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].. PubMed. 65(4). 250–7. 1 indexed citations
20.
Bergemann, N., et al.. (1983). [Propafenon and alcohol: effect of this combination of behavioral performance and the subjective condition in healthy volunteers].. PubMed. 33(11). 1598–602. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolás David Ramírez Breakdown of academic impact, for papers by Gerald Oppenheim Breakdown of academic impact, for papers by Ivo Caers Breakdown of academic impact, for papers by Abdulla A.-B. Badawy Breakdown of academic impact, for papers by Cheng‐Cheng Hsiao Breakdown of academic impact, for papers by Vicki L. Ellingrod Breakdown of academic impact, for papers by Cherry W. Jackson Breakdown of academic impact, for papers by Carla Conroy Breakdown of academic impact, for papers by Xiaoyun Wang Breakdown of academic impact, for papers by Jacoline Neuteboom
Rankless by CCL
2026